Published in final edited form as:

Curr Opin Neurobiol. 2014 December ; 0: 103–108. doi:10.1016/j.conb.2014.07.006.

Hypocretin (orexin) neuromodulation of stress and reward pathways

William J. Giardino and Luis de Lecea

Department of Psychiatry and Behavioral Sciences Stanford University 1201 Welch Rd., P154
Stanford, CA, USA 94305 phone: 650-736-4389

Abstract

Hypocretin (also known as orexin) is a peptide neuromodulator that is expressed exclusively in the lateral hypothalamic area and plays a fundamental role in wakefulness and arousal. Chronic stress and compulsive drug-seeking are two examples of dysregulated states of hyperarousal that are influenced by hypocretin transmission throughout hypothalamic, extended amygdala, brainstem, and mesolimbic pathways. Here, we review current advances in the understanding of hypocretin's modulatory actions underlying conditions of negative and positive emotional valence, focusing particularly on mechanisms that facilitate adaptive (and maladaptive) responses to stressful or rewarding environmental stimuli. We conclude by discussing progress toward integrated theories for hypocretin modulation of divergent behavioral domains.

Introduction

The hypocretins (also known as orexins) are two secreted neuropeptides (Hcrt1, Hcrt2) derived from the same preprohypocretin gene that bind to two G-protein-coupled receptors (HcrtR1, HcrtR2) [1–3]. Both hypocretins are expressed exclusively in the lateral hypothalamic area (LH), therefore both are referred to here as hypocretin (Hcrt). LH-Hcrt neurons are inactive during sleep, but become activated during wakefulness, likely to promote goal-oriented behavior and energy homeostasis [4,5]. Direct manipulations of LH-Hcrt neurons using *in vivo* optogenetics revealed their key role in increasing the probability of sleep-to-wake transitions through HcrtR signaling in norepinephrine (NE) neurons of the locus coeruleus (LC) [6,7]. While LH-Hcrt neurons project widely [8], this review covers Hcrt's modulatory actions within the paraventricular nucleus of the hypothalamus (PVN), bed nucleus of the stria terminalis (BNST), central and basolateral nuclei of the amygdala (CeA, BLA), LC, ventral tegmental area (VTA), and nucleus accumbens (NAcc). Rather than providing a comprehensive summary of the literature, we focus on articles published in

© 2014 Elsevier Ltd. All rights reserved

willgiar@stanford.edu

llecea@stanford.edu

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of Interest Nothing declared

the last three years that examine Hcrt neuromodulation of stress- and addiction-related phenomena.

Multiple lines of evidence identify Hcrt as a pro-stress modulator, adding complexity to the prevailing view of Hcrt as a reward-related signal. For example, intracerebroventricular (i.c.v.) Hcrt administration enhances anxiety-like behavior [9] and decreases brain reward function, reflected by increased thresholds in the classical intracranial self-stimulation (ICSS) procedure [10]. Interestingly, Hcrt's effects on the ICSS threshold are mediated by corticotropin-releasing factor (CRF), the prototypical stress neuropeptide [11]. CRF released from the PVN activates the hypothalamic-pituitary-adrenal (HPA) stress axis, resulting in increased levels of adrenocorticotropin hormone (ACTH) and corticosterone (or cortisol; CORT). Hcrt administered i.c.v. also elevates ACTH and CORT levels [12], supporting the hypothesis that Hcrt possesses CRF-dependent anti-reward properties [11]. Yet, an extensive literature describes Hcrt-mediated positive modulation of the mesolimbic VTA dopamine (DA) reward system. Hcrt robustly innervates the VTA [13], induces excitatory synaptic plasticity in VTA-DA neurons [14,15], and causes DA release in VTA target regions [16,17]. Reward-seeking behavior (i.e., expression of conditioned place preference, operant self-administration, or reinstatement of either) is associated with activation of Hcrt neurons, and largely attenuated by systemic HcrtR blockade [18,19].

Thus, Hcrt is anatomically and functionally poised to modulate neural activity in arousal-related conditions of both negative and positive emotional valence. In reviewing the most recent findings on this topic, we discuss several mechanisms by which dysfunction of Hcrt modulation could underlie behavioral states associated with stress- and addiction-related psychiatric disorders.

Hypocretin Interactions with CRF Stress Pathways

Hcrt-containing efferents of the LH target the hypothalamus and extended amygdala, particularly the CRF-enriched nuclei of the PVN, BNST, and CeA [20–22]. I.c.v. infusion of Hcrt activates PVN-CRF neurons [23] and elevates HPA hormones [12], suggesting that Hcrt directly modulates the CRF-mediated neuroendocrine output. Furthermore, the anxiolytic effects of HcrtR1 blockade are associated with reduced neural activation in the BNST and CeA [24]. Together with the CRF-dependent effects of Hcrt on the ICSS threshold described above, these data suggest that Hcrt interactions with CRF neurons of the PVN, BNST, and/or CeA are associated with anxiogenic and anhedonic states [11]. Importantly, Hcrt-CRF interactions are reciprocal, as CRF provides excitatory input to Hcrt neurons, and Hcrt neurons undergo CRF-dependent transcriptional activation following exposure to various stressors [25].

Acute withdrawal following chronic drug exposure encompasses a stress-like state of hyperarousal, and withdrawal from morphine and nicotine increases transcriptional activity in Hcrt neurons of the LH, as well as CRF neurons of the PVN and CeA [26,27]. Morphine withdrawal-induced activation of the PVN, BNST, and CeA is decreased by systemic HcrtR1 blockade [27], and local HcrtR1 antagonism in the PVN reduces the behavioral expression of nicotine withdrawal [28]. These findings raise the possibility that Hcrt

modulation of CRF neurons participates in the chronically-relapsing, negative affective state that characterizes drug addiction. Indeed, one landmark study found that i.c.v. Hcrt mimicked the ability of stress to reinstate operant cocaine-seeking in a CRF-dependent manner [10]. Nevertheless, it remains unclear whether this form of Hcrt modulation involves CRF neurons in the PVN, BNST, or CeA.

Hypocretin Modulation in the BNST and Amygdala

As with the PVN, the BNST connects reciprocally with Hcrt neurons [8,29]. However, while PVN-CRF neurons are mostly glutamatergic, BNST-CRF neurons are primarily GABAergic [30], thereby offering diverse mechanisms for Hcrt modulation of stress circuits. In one recent study, slice application of Hcrt to neurons in the CRF-enriched dorsolateral BNST (dlBNST) of adult mice depressed excitatory post-synaptic currents (EPSCs) in a HcrtR1-specific manner [31]. Interestingly, these effects on excitatory dlBNST transmission mimicked those of yohimbine, the α -2 NE receptor antagonist known to reinstate operant alcohol-seeking through a HcrtR1-mediated mechanism [32]. In a separate study, slice application of Hcrt depolarized a subset of neurons in the posterior BNST of adult rats [33]. These effects contrast with those observed in mice [31], but are consistent with the ability of intra-BNST Hcrt to increase anxiety-like behavior via NMDA receptor activation [33]. Even a single subregion of the BNST can display tremendous cellular heterogeneity [30], and Hcrt's modulatory actions undoubtedly vary across cell types, highlighting the need for detailed studies of Hcrt's effects in genetically- or physiologically-defined BNST neurons.

Intra-CeA Hcrt infusion elevates anxiety levels [34], and Hcrt slice application excites “low-threshold burst” output neurons in the medial division of the CeA [35]. Together with evidence that i.c.v. Hcrt activates CeA-CRF neurons [23], these data suggest a mechanism in which Hcrt potentiation of CeA excitability underlies a stress-like state (perhaps by releasing output neurons from inhibitory GABAergic control [34]). Elsewhere in the amygdala, Arendt et al. used RNA interference in adult mice to show that BLAHcrtR2 signaling is anxiolytic rather than anxiogenic [36]. Although this finding contrasts with the reported effects of intra-CeA Hcrt, it bears resemblance to a recent study that uncovered opposite consequences of HcrtR1 and HcrtR2 deletion on depressive-like behaviors in mice [37].

Hypocretin Modulation in the LC

LC-NE neurons are a major target of Hcrt neurons, and combinatorial optogenetics revealed the necessity of LC-NE activity for Hcrt-mediated awakenings [7]. Additionally, LC-NE neurons play a critical role in the stress response [38]. NE-induced plasticity at GABAergic synapses in the PVN regulates HPA-axis activity [39], and the relevance of BNST-NE signaling to stress and reward function has been reviewed [40]. In one recent study of Hcrt-NE interactions, Sears et al. used optogenetic and pharmacological approaches to demonstrate that excitatory LC-HcrtR1 signaling accentuates the strength of fear memories through downstream NE signaling in the lateral amygdala [41]. Thus, disturbances in Hcrt

modulation of brainstem NE nuclei may underlie conditions of dysregulated threat assessment via indirect potentiation of amygdala activity.

Hypocretin Modulation in the VTA

VTA-DA neuron burst firing is sufficient to produce conditioned reward [42], and Hcrt neurons project strongly to the VTA [13], forming appositional contacts with DA neurons [43]. VTA-DA neurons demonstrate increased EPSC amplitudes and firing rates upon Hcrt application, and display HcrtR1-dependent excitatory synaptic plasticity following cocaine exposure. The precise mechanisms underlying these forms of modulation have been reviewed elsewhere in detail [14,15]. Intra-VTA infusion of Hcrt increases DA efflux in the prefrontal cortex and NAcc, suggesting that Hcrt modulation of the VTA promotes appetitive responding and motivation for salient environmental cues via enhanced DA receptor signaling [16,17]. An expansive literature describes the contributions of Hcrt neurons and HcrtR signaling to reward-related behavior [18,19]. Here, we simply highlight a few recent examples that add to the growing understanding of how Hcrt modulation of the VTA fits within the context of brain reward function and drug-seeking behavior.

Srinivasan et al. found that intra-VTA HcrtR antagonism reduced lever-pressing for 20% alcohol, and replicated previous findings by demonstrating that Hcrt increased the firing rate of putative VTA-DA neurons, indicating that Hcrt promotes alcohol-seeking by increasing VTA-DA excitability [44]. Mahler et al. reported the necessity of simultaneous Hcrt and glutamate transmission within the VTA for cue-induced reinstatement of operant cocaine-seeking [45], and Morgan et al. established that prenatal nicotine exposure enhances Hcrt innervation of VTA-DA neurons, hinting at a developmental role for Hcrt in drug-induced mesolimbic plasticity [43].

Hypocretin Modulation in the NAcc

In addition to modulating DA activity at the level of the VTA, two new studies examine how Hcrt inputs to the NAcc could further amplify reward-related effects associated with striatal DA release. Mori et al. described a subpopulation of neurons in the NAcc shell that displayed a synergistic increase in firing rate upon combinatorial application of Hcrt and DA, relative to Hcrt alone [46]. Patyal et al. used voltammetry in NAcc shell slices to reveal a glutamate-dependent mechanism in which Hcrt enhanced DA levels following phasic, but not tonic, patterns of electrical stimulation [47]. Together with data implicating NAcc-HcrtR signaling in stress-induced reinstatement of morphine conditioned place preference [48] and cue-induced reinstatement of nicotine-seeking [49], these findings identify the NAcc (particularly the shell) as an additional site through which Hcrt could promote reward-based behavior via augmentation of DA release from VTA terminals.

Conclusions

Recent studies on Hcrt modulation have identified diverse mechanisms that point toward both pro-stress (PVN, BNST, CeA, LC) and anti-stress/pro-reward (BLA, VTA, NAcc) behavioral consequences (Figure 1). Future investigation of the discussed pathways may shed light on clinical findings that highlight Hcrt's involvement in the response to both

negative and positive motivational situations. For example, Hcrt-deficient patients display impaired amygdala activation following exposure to conditioned aversive stimuli, yet human amygdala Hcrt levels are elevated during laughter and affiliative social interactions [50,51]. Below, we discuss potential explanations for the complex and occasionally bi-directional effects of Hcrt neuromodulation on emotional behavior.

Previous efforts to integrate the disparate behavioral profiles of Hcrt resulted in a “divergent efferent hypothesis,” based on the apparent stress- vs. reward-responsiveness of Hcrt neurons in the dorsomedial and perifornical hypothalamic nuclei vs. the lateral division of the LH. Specifically, Harris and Aston-Jones suggested that a stress-reward dichotomy could be explained by the differential strength of Hcrt projections from these two subpopulations to the LC vs. the VTA [52]. However, Gonzalez et al. performed a rigorous analysis of the anatomical locations of LC- and VTA-projecting Hcrt neurons and failed to find a pattern consistent with that proposed by the divergent efferent hypothesis [53]. Nevertheless, the LH is a particularly heterogeneous structure, and functional segregation of Hcrt neuron subpopulations using viral-assisted circuit mapping is theoretically feasible with optical and chemicogenetic tools.

An alternative theory is that the stress response, drug reward, and seeking behavior are all linked to increased Hcrt tone simply because these states are associated with enhanced levels of arousal. Yet, the concept of Hcrt as a pan-arousal modulator remains controversial. Rather, some have suggested that Hcrt acts specifically in response to environmental challenges to facilitate transitions between contrasting behavioral states [1], or even that Hcrt displays selectivity for precise emotional domains such as excitement and anger, rather than wakefulness *per se* [50].

A further parsimonious explanation is that Hcrt peptides (Hcrt1 and Hcrt2) produce behavioral specificity via their differential actions at Hcrt receptors (HcrtR1 and HcrtR2), which are expressed in varying ratios across diverse cell types [1]. Apparent differences in the effects of Hcrt1 vs. Hcrt2 on VTA-DA neurons have been documented [15,44], and emerging data provide an intriguing basis for the hypothesis that HcrtR1 and HcrtR2 signaling oppositely modulate anxiety- and depressive-like behaviors [36,37]. Such a theory also predicts that varying magnitudes of Hcrt release could initiate divergent behaviors in a concentration-dependent manner, based on the relative affinities of Hcrt peptides for their receptors.

Finally, Hcrt modulation of behavior is unlikely a static phenomenon, and may be particularly sensitive to experiential effects. For example, region-specific modulation of neural circuits by Hcrt could promote appetitive vs. aversive responding depending on an individual's prior experience with stress or addictive substances. The observation that repeated stress flips the hedonic valence of intra-NAcc CRF treatment [54] highlights the powerful potential of environmental factors to interact with biological systems that are capable of divergent behavioral responses. The application of these ideas to the study of Hcrt could be especially valuable, given the remarkably broad range of Hcrt's anatomical projections and modulatory outcomes described herein.

In summary, continued study of Hcrt modulation of stress and reward pathways (particularly Hcrt interactions with CRF, DA, and NE systems) may provide critical insight into the relationship between HcrtR signaling and behaviors relevant to psychiatric disease symptoms. Differential effects of Hcrt on plasticity of glutamatergic (PVN, BLA, VTA) and GABAergic (BNST, CeA, VTA) circuitry will be especially important in understanding persistent Hcrt-induced adaptations related to stress and reward function. Recent methodological advances now allow detailed interrogation of precise neural subpopulations, and we anticipate significant progress toward understanding the complex and diverse roles of Hcrt modulation with future application of these tools.

Acknowledgements

We thank Drs. Ada D. Eban-Rothschild and Andrew J. Whittle for helpful comments on this manuscript. Grant support from the National Institutes of Health was provided to WJG (F32 AA022832) and LdL (R01 MH83702, R01 MH87592).

References

Papers of particular interest have been highlighted as:

* of special interest

** of outstanding interest

1. Carter ME, Borg JS, de Lecea L. The brain hypocretins and their receptors: mediators of allostatic arousal. *Curr Opin Pharmacol*. 2009; 9:39–45. [PubMed: 19185540]
2. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS 2nd, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. *Proc Natl Acad Sci U S A*. 1998; 95:322–327. [PubMed: 9419374]
3. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell*. 1998; 92:573–585. [PubMed: 9491897]
4. Mileykovskiy BY, Kiyashchenko LI, Siegel JM. Behavioral correlates of activity in identified hypocretin/orexin neurons. *Neuron*. 2005; 46:787–798. [PubMed: 15924864]
5. Lee MG, Hassani OK, Jones BE. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. *J Neurosci*. 2005; 25:6716–6720. [PubMed: 16014733]
6. Adamantidis AR, Zhang F, Aravanis AM, Deisseroth K, de Lecea L. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. *Nature*. 2007; 450:420–424. [PubMed: 17943086]
7. Carter ME, Brill J, Bonnavion P, Huguenard JR, Huerta R, de Lecea L. Mechanism for Hypocretin-mediated sleep-to-wake transitions. *Proc Natl Acad Sci U S A*. 2012; 109:E2635–2644. [PubMed: 22955882] ** This study implemented various combinations of excitatory and inhibitory optogenetic methods *in vivo* to study the relationship between LH-Hcrt and LC-NE neuron populations in sleep-to-wake transitions, providing causal evidence for Hcrt's critical role in arousal via LC modulation.
8. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, Kilduff TS. Neurons containing hypocretin (orexin) project to multiple neuronal systems. *J Neurosci*. 1998; 18:9996–10015. [PubMed: 9822755]
9. Suzuki M, Beuckmann CT, Shikata K, Ogura H, Sawai T. Orexin-A (hypocretin-1) is possibly involved in generation of anxiety-like behavior. *Brain Res*. 2005; 1044:116–121. [PubMed: 15862796]

10. Boutrel B, Kenny PJ, Specio SE, Martin-Fardon R, Markou A, Koob GF, de Lecea L. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. *Proc Natl Acad Sci U S A*. 2005; 102:19168–19173. [PubMed: 16357203]
11. Hata T, Chen J, Ebihara K, Date Y, Ishida Y, Nakahara D. Intra-ventral tegmental area or intracerebroventricular orexin-A increases the intra-cranial self-stimulation threshold via activation of the corticotropin-releasing factor system in rats. *Eur J Neurosci*. 2011; 34:816–826. [PubMed: 21848921] * These experiments provide a key replication of early data showing that i.c.v. Hcrt infusion increases the ICSS threshold, and expand these findings to demonstrate that this action of Hcrt can be mediated specifically through the VTA, and in a CRF receptor-dependent manner.
12. Kuru M, Ueta Y, Serino R, Nakazato M, Yamamoto Y, Shibuya I, Yamashita H. Centrally administered orexin/hypocretin activates HPA axis in rats. *Neuroreport*. 2000; 11:1977–1980. [PubMed: 10884055]
13. Fadel J, Deutch AY. Anatomical substrates of orexin-dopamine interactions: lateral hypothalamic projections to the ventral tegmental area. *Neuroscience*. 2002; 111:379–387. [PubMed: 11983323]
14. Borgland SL, Ungless MA, Bonci A. Convergent actions of orexin/hypocretin and CRF on dopamine neurons: Emerging players in addiction. *Brain Res*. 2010; 1314:139–144. [PubMed: 19891960]
15. Baimel C, Borgland SL. Hypocretin modulation of drug-induced synaptic plasticity. *Prog Brain Res*. 2012; 198:123–131. [PubMed: 22813972]
16. Vittoz NM, Berridge CW. Hypocretin/orexin selectively increases dopamine efflux within the prefrontal cortex: involvement of the ventral tegmental area. *Neuropsychopharmacology*. 2006; 31:384–395. [PubMed: 15988471]
17. Narita M, Nagumo Y, Hashimoto S, Khotib J, Miyatake M, Sakurai T, Yanagisawa M, Nakamachi T, Shioda S, Suzuki T. Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. *J Neurosci*. 2006; 26:398–405. [PubMed: 16407535]
18. Boutrel B, Steiner N, Halfon O. The hypocretins and the reward function: what have we learned so far? *Front Behav Neurosci*. 2013; 7:59. [PubMed: 23781178]
19. Aston-Jones G, Smith RJ, Sartor GC, Moorman DE, Massi L, Tahsili-Fahadan P, Richardson KA. Lateral hypothalamic orexin/hypocretin neurons: A role in reward-seeking and addiction. *Brain Res*. 2010; 1314:74–90. [PubMed: 19815001]
20. Baldo BA, Daniel RA, Berridge CW, Kelley AE. Overlapping distributions of orexin/hypocretin- and dopamine-beta-hydroxylase immunoreactive fibers in rat brain regions mediating arousal, motivation, and stress. *J Comp Neurol*. 2003; 464:220–237. [PubMed: 12898614]
21. Ciriello J, Rosas-Arellano MP, Solano-Flores LP, de Oliveira CV. Identification of neurons containing orexin-B (hypocretin-2) immunoreactivity in limbic structures. *Brain Res*. 2003; 967:123–131. [PubMed: 12650973]
22. Schmitt O, Usunoff KG, Lazarov NE, Itzev DE, Eipert P, Rolfs A, Wree A. Orexinergic innervation of the extended amygdala and basal ganglia in the rat. *Brain Struct Funct*. 2012; 217:233–256. [PubMed: 21935673]
23. Sakamoto F, Yamada S, Ueta Y. Centrally administered orexin-A activates corticotropin-releasing factor-containing neurons in the hypothalamic paraventricular nucleus and central amygdaloid nucleus of rats: possible involvement of central orexins on stress-activated central CRF neurons. *Regul Pept*. 2004; 118:183–191. [PubMed: 15003835]
24. Johnson PL, Samuels BC, Fitz SD, Federici LM, Hammes N, Early MC, Truitt W, Lowry CA, Shekhar A. Orexin 1 receptors are a novel target to modulate panic responses and the panic brain network. *Physiol Behav*. 2012; 107:733–742. [PubMed: 22554617]
25. Winsky-Sommerer R, Yamanaka A, Diano S, Borok E, Roberts AJ, Sakurai T, Kilduff TS, Horvath TL, de Lecea L. Interaction between the corticotropin-releasing factor system and hypocretins (orexins): a novel circuit mediating stress response. *J Neurosci*. 2004; 24:11439–11448. [PubMed: 15601950]

26. Georgescu D, Zachariou V, Barrot M, Mieda M, Willie JT, Eisch AJ, Yanagisawa M, Nestler EJ, DiLeone RJ. Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. *J Neurosci*. 2003; 23:3106–3111. [PubMed: 12716916]
27. Laorden ML, Ferenczi S, Pinter-Kubler B, Gonzalez-Martin LL, Lasheras MC, Kovacs KJ, Milanes MV, Nunez C. Hypothalamic orexin—a neurons are involved in the response of the brain stress system to morphine withdrawal. *PLoS One*. 2012; 7:e36871. [PubMed: 22590628]
28. Plaza-Zabala A, Flores A, Maldonado R, Berrendero F. Hypocretin/orexin signaling in the hypothalamic paraventricular nucleus is essential for the expression of nicotine withdrawal. *Biol Psychiatry*. 2012; 71:214–223. [PubMed: 21831361]
29. Yoshida K, McCormack S, Espana RA, Crocker A, Scammell TE. Afferents to the orexin neurons of the rat brain. *J Comp Neurol*. 2006; 494:845–861. [PubMed: 16374809]
30. Dabrowska J, Hazra R, Guo JD, Dewitt S, Rainnie DG. Central CRF neurons are not created equal: phenotypic differences in CRF-containing neurons of the rat paraventricular hypothalamus and the bed nucleus of the stria terminalis. *Front Neurosci*. 2013; 7:156. [PubMed: 24009552]
31. Conrad KL, Davis AR, Silberman Y, Sheffler DJ, Shields AD, Saleh SA, Sen N, Matthies HJ, Javitch JA, Lindsley CW, et al. Yohimbine depresses excitatory transmission in BNST and impairs extinction of cocaine place preference through orexin-dependent, norepinephrine-independent processes. *Neuropsychopharmacology*. 2012; 37:2253–2266. [PubMed: 22617356]
32. Richards JK, Simms JA, Steensland P, Taha SA, Borgland SL, Bonci A, Bartlett SE. Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats. *Psychopharmacology (Berl)*. 2008; 199:109–117. [PubMed: 18470506]
33. Lungwitz EA, Molosh A, Johnson PL, Harvey BP, Dirks RC, Dietrich A, Minick P, Shekhar A, Truitt WA. Orexin-A induces anxiety-like behavior through interactions with glutamatergic receptors in the bed nucleus of the stria terminalis of rats. *Physiol Behav*. 2012; 107:726–732. [PubMed: 22652097]
34. Avolio E, Alo R, Carelli A, Canonaco M. Amygdalar orexinergic-GABAergic interactions regulate anxiety behaviors of the Syrian golden hamster. *Behav Brain Res*. 2011; 218:288–295. [PubMed: 21074570]
35. Bisetti A, Cvetkovic V, Serafin M, Bayer L, Machard D, Jones BE, Muhlethaler M. Excitatory action of hypocretin/orexin on neurons of the central medial amygdala. *Neuroscience*. 2006; 142:999–1004. [PubMed: 16996221]
36. Arendt DH, Hassell J, Li H, Achua JK, Guarnieri DJ, Dileone RJ, Ronan PJ, Summers CH. Anxiolytic function of the orexin 2/hypocretin A receptor in the basolateral amygdala. *Psychoneuroendocrinology*. 2014; 40:17–26. [PubMed: 24485472] * These authors selectively downregulated levels of either HcrtR1 or HcrtR2 within the BLA, providing the first evidence that BLA-HcrtR2 signaling is in fact anxiolytic, rather than anxiogenic.
37. Scott MM, Marcus JN, Pettersen A, Birnbaum SG, Mochizuki T, Scammell TE, Nestler EJ, Elmquist JK, Lutter M. HcrtR1 and 2 signaling differentially regulates depression-like behaviors. *Behav Brain Res*. 2011; 222:289–294. [PubMed: 21377495]
38. Valentino RJ, Van Bockstaele E. Convergent regulation of locus coeruleus activity as an adaptive response to stress. *Eur J Pharmacol*. 2008; 583:194–203. [PubMed: 18255055]
39. Inoue W, Baimoukhametova DV, Fuzesi T, Wamsteeker Cusulin JJ, Koblinger K, Whelan PJ, Pittman QJ, Bains JS. Noradrenaline is a stress-associated metaplastic signal at GABA synapses. *Nat Neurosci*. 2013; 16:605–612. [PubMed: 23563580]
40. Flavin SA, Winder DG. Noradrenergic control of the bed nucleus of the stria terminalis in stress and reward. *Neuropharmacology*. 2013; 70:324–330. [PubMed: 23466330]
41. Sears RM, Fink AE, Wigstrand MB, Farb CR, de Lecea L, Ledoux JE. Orexin/hypocretin system modulates amygdala-dependent threat learning through the locus coeruleus. *Proc Natl Acad Sci U S A*. 2013; 110:20260–20265. [PubMed: 24277819] * These authors optogenetically stimulated Hcrt terminals in the LC to show that fear memories could be strengthened by excitatory Hcrt modulation of LC activity and subsequent downstream amygdala NE release.

42. Tsai HC, Zhang F, Adamantidis A, Stuber GD, Bonci A, de Lecea L, Deisseroth K. Phasic firing in dopaminergic neurons is sufficient for behavioral conditioning. *Science*. 2009; 324:1080–1084. [PubMed: 19389999]
43. Morgan AJ, Harrod SB, Lacy RT, Stanley EM, Fadel JR. Intravenous prenatal nicotine exposure increases orexin expression in the lateral hypothalamus and orexin innervation of the ventral tegmental area in adult male rats. *Drug Alcohol Depend*. 2013; 132:562–570. [PubMed: 23664126]
44. Srinivasan S, Simms JA, Nielsen CK, Lieske SP, Bito-Onon JJ, Yi H, Hopf FW, Bonci A, Bartlett SE. The dual orexin/hypocretin receptor antagonist, almorexant, in the ventral tegmental area attenuates ethanol self-administration. *PLoS One*. 2012; 7:e44726. [PubMed: 23028593]
45. Mahler SV, Smith RJ, Aston-Jones G. Interactions between VTA orexin and glutamate in cue-induced reinstatement of cocaine seeking in rats. *Psychopharmacology (Berl)*. 2013; 226:687–698. [PubMed: 22411428]
46. Mori K, Kim J, Sasaki K. Electrophysiological effects of orexin-B and dopamine on rat nucleus accumbens shell neurons in vitro. *Peptides*. 2011; 32:246–252. [PubMed: 21055430]
47. Patyal R, Woo EY, Borgland SL. Local hypocretin-1 modulates terminal dopamine concentration in the nucleus accumbens shell. *Front Behav Neurosci*. 2012; 6:82. [PubMed: 23226119]
48. Qi K, Wei C, Li Y, Sui N. Orexin receptors within the nucleus accumbens shell mediate the stress but not drug priming-induced reinstatement of morphine conditioned place preference. *Front Behav Neurosci*. 2013; 7:144. [PubMed: 24133421]
49. Plaza-Zabala A, Flores A, Martin-Garcia E, Saravia R, Maldonado R, Berrendero F. A role for hypocretin/orexin receptor-1 in cue-induced reinstatement of nicotine-seeking behavior. *Neuropsychopharmacology*. 2013; 38:1724–1736. [PubMed: 23518606]
50. Blouin AM, Fried I, Wilson CL, Staba RJ, Behnke EJ, Lam HA, Maidment NT, Karlsson KAE, Lapierre JL, Siegel JM. Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction. *Nat Commun*. 2013; 4:1547. [PubMed: 23462990] ** By quantifying brain region-specific peptide levels in human patients *in vivo*, this article describes the relationship between Hcrt and specific behavioral states, highlighting elevations in Hcrt during positive emotions and social interactions.
51. Ponz A, Khatami R, Poryazova R, Werth E, Boesiger P, Schwartz S, Bassetti CL. Reduced amygdala activity during aversive conditioning in human narcolepsy. *Ann Neurol*. 2010; 67:394–398. [PubMed: 20373351]
52. Harris GC, Aston-Jones G. Arousal and reward: a dichotomy in orexin function. *Trends Neurosci*. 2006; 29:571–577. [PubMed: 16904760]
53. Gonzalez JA, Jensen LT, Fugger L, Burdakov D. Convergent inputs from electrically and topographically distinct orexin cells to locus coeruleus and ventral tegmental area. *Eur J Neurosci*. 2012; 35:1426–1432. [PubMed: 22507526]
54. Lemos JC, Wanat MJ, Smith JS, Reyes BA, Hollon NG, Van Bockstaele EJ, Chavkin C, Phillips PE. Severe stress switches CRF action in the nucleus accumbens from appetitive to aversive. *Nature*. 2012; 490:402–406. [PubMed: 22992525] * By assessing the impact of repeated forced swim on CRF-induced place conditioning, these authors illustrate the ability of stress to switch the hedonic valence of intra-NAcc CRF treatment from appetitive to aversive.

Highlights

- Hypocretin modulates neural transmission in stress- and reward-related brain areas
- Interactions between hypocretin and CRF can produce negative affective states
- Hypocretin-induced mesolimbic dopamine plasticity may potentiate reward-seeking
- Dysregulated hypocretin modulation may underlie disorders of stress and addiction

Figure 1.

LH-Hcrt neurons project widely, including to the PVN, BNST, CeA, BLA, LC, VTA, and NAcc. Recent evidence implicates Hcrt modulation of CRF neurons of the PVN, BNST, and CeA in the negative affective states associated with anhedonia, drug withdrawal, HPA-axis activation, and anxiogenesis. Primarily glutamatergic vs. GABAergic phenotypes of PVN-CRF vs. BNST-CRF neurons provide diverse mechanisms for Hcrt modulation of stress circuitry. Preliminary evidence implicates BLA-HcrtR2 signaling in anxiolysis rather than anxiogenesis. Hcrt innervation of LC-NE neurons participates in sleep-to-wake transitions, and strengthens fear memories via subsequent LC-NE release in the amygdala. Hcrt modulation of excitatory synaptic plasticity in VTA-DA neurons is well-studied. Together with potentiation of DA release at the level of the NAcc shell, Hcrt may promote motivational responding and drug-seeking behavior via enhanced DA receptor signaling.